NASDAQ:FOLDAmicus Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.48 +0.29 (+2.38 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$11.89Now: $12.48▼$12.5250-Day Range$10.03MA: $11.73▼$12.8252-Week Range$6.25Now: $12.48▼$13.39Volume1.78 million shsAverage Volume2.76 million shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAmicus Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.50, Amicus Therapeutics has a potential upside of 64.3% from its current price of $12.48.Amount of Analyst CoverageAmicus Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesAmicus Therapeutics has received 473 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAmicus Therapeutics has received 311 “underperform” votes. (Add your “underperform” vote.)Community SentimentAmicus Therapeutics has received 60.33% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Amicus Therapeutics and other stocks. Vote “Outperform” if you believe FOLD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FOLD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,422,509.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Amicus Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Amicus Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 8.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FOLD Previous Symbol CUSIP03152W10 CIK1178879 Webwww.amicusrx.com Phone609-662-2000Debt Debt-to-Equity Ratio0.50 Current Ratio4.45 Quick Ratio4.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$182.24 million Price / Sales17.64 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book8.00Profitability EPS (Most Recent Fiscal Year)($1.31) Net Income$-356,390,000.00 Net Margins-155.73% Return on Equity-63.24% Return on Assets-37.83%Miscellaneous Employees508 Outstanding Shares257,660,000Market Cap$3.21 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:FOLD Rates by TradingView Receive FOLD News and Ratings via Email Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions How has Amicus Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FOLD stock has increased by 55.0% and is now trading at $12.4750. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Amicus Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amicus Therapeutics. When is Amicus Therapeutics' next earnings date? Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Amicus Therapeutics. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.07. The biopharmaceutical company earned $60.53 million during the quarter, compared to the consensus estimate of $57.21 million. Amicus Therapeutics had a negative return on equity of 63.24% and a negative net margin of 155.73%. View Amicus Therapeutics' earnings history. What guidance has Amicus Therapeutics issued on next quarter's earnings? Amicus Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $257.09 million. What price target have analysts set for FOLD? 7 brokerages have issued 1 year price objectives for Amicus Therapeutics' stock. Their forecasts range from $12.50 to $31.00. On average, they anticipate Amicus Therapeutics' share price to reach $20.50 in the next year. This suggests a possible upside of 64.3% from the stock's current price. View analysts' price targets for Amicus Therapeutics. What are Wall Street analysts saying about Amicus Therapeutics stock? Here are some recent quotes from research analysts about Amicus Therapeutics stock: 1. According to Zacks Investment Research, "Amicus realized revenues from sales of its only marketed drug, Galafold in the second quarter. The uptake of Galafold has been strong. The company is on track to achieve its 2019 key priorities, including, Pompe late-stage development program, and the development of the gene-therapy pipeline. With a very successful, now global, commercial precision medicine product in Fabry disease, a late-stage phase III program in late onset Pompe disease and rapidly advancing gene therapy programs for rare diseases in development, the company is well positioned to achieve its target. However, it depends heavily on Galafold sales, which is a concern. Shares of the company have outperformed the industry year to date. Loss estimates narrowed ahead of Q3 earnings. The company has a dismal record of earnings surprises in the recent quarters." (11/4/2019) 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our current 12-month, $18 price target on shares of Amicus is derived from a 13-year DCF-based, sum-of-the-parts analysis driven by: beta of 1.70; terminal growth rate of 0.5%; risk premium of 4.93%; estimated WACC of 10.8%; and tax rate of 12.5% beginning in FY 2030. Galafold and AT- GAA at 42% each, plus the two Batten disease programs programs at a combined 16%, make up our rNPV. For AT-GAA, we assume a POS of 70%, whereas for CLN6 we assume a 45% POS and assign a 10% POS for CLN3." (8/1/2019) Has Amicus Therapeutics been receiving favorable news coverage? News stories about FOLD stock have trended extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amicus Therapeutics earned a news impact score of -5.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAmicus Therapeutics. Who are some of Amicus Therapeutics' key competitors? Some companies that are related to Amicus Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Inovio Pharmaceuticals (INO), Exelixis (EXEL), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Cara Therapeutics (CARA) and Micron Technology (MU). Who are Amicus Therapeutics' key executives? Amicus Therapeutics' management team includes the following people: Mr. John F. Crowley, Chairman & CEO (Age 52)Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)Dr. Jay A. Barth, Chief Medical Officer (Age 55)Ms. Daphne E. Quimi, Chief Financial Officer (Age 53) What is Amicus Therapeutics' stock symbol? Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD." Who are Amicus Therapeutics' major shareholders? Amicus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.77%), Redmile Group LLC (9.77%), BlackRock Inc. (8.25%), Morgan Stanley (4.80%), Morgan Stanley (4.80%) and Janus Henderson Group PLC (4.51%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Kurt J Andrews, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc and William D Baird III. View institutional ownership trends for Amicus Therapeutics. Which institutional investors are selling Amicus Therapeutics stock? FOLD stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Jennison Associates LLC, Pictet Asset Management Ltd., Nuveen Asset Management LLC, Sphera Funds Management LTD., AXA, Two Sigma Investments LP, and Wellington Management Group LLP. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Jay Barth, John F Crowley, Margaret G Mcglynn, and Michael Raab. View insider buying and selling activity for Amicus Therapeutics. Which institutional investors are buying Amicus Therapeutics stock? FOLD stock was bought by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Deutsche Bank AG, Fairmount Funds Management LLC, Janus Henderson Group PLC, Assenagon Asset Management S.A., BlackRock Inc., Geode Capital Management LLC, and Asymmetry Capital Management L.P.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive, and Perceptive Advisors Llc. View insider buying and selling activity for Amicus Therapeutics. How do I buy shares of Amicus Therapeutics? Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Amicus Therapeutics' stock price today? One share of FOLD stock can currently be purchased for approximately $12.48. How big of a company is Amicus Therapeutics? Amicus Therapeutics has a market capitalization of $3.21 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe. What is Amicus Therapeutics' official website? The official website for Amicus Therapeutics is www.amicusrx.com. How can I contact Amicus Therapeutics? Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at ir.amicusrx.com. This page was last updated on 5/31/2020 by MarketBeat.com Staff
